• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    2/10/22 8:27:59 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MDT alert in real time by email
    SC 13G/A 1 tv01412-medtronicplc.htm SCHEDULE 13G/A medtronicplc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 6)*

    Name of issuer:  Medtronic plc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  G5960L103

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  G5960L103

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    2,126,561

    7.  SOLE DISPOSITIVE POWER

    107,726,072

    8.  SHARED DISPOSITIVE POWER

    5,427,638

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    113,153,710

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.42%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Medtronic plc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    20 On Hatch, Lower Hatch Street
    Dublin 2

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    G5960L103

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $MDT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDT

    DatePrice TargetRatingAnalyst
    6/30/2025Underperform → Peer Perform
    Wolfe Research
    6/16/2025$110.00Outperform
    Leerink Partners
    3/4/2025$92.00 → $107.00Neutral → Buy
    Citigroup
    10/10/2024$98.00 → $105.00Sector Perform → Outperform
    RBC Capital Mkts
    8/21/2024$92.00 → $94.00Perform
    Oppenheimer
    8/15/2024$76.00 → $90.00Sell → Neutral
    UBS
    8/14/2024$100.00 → $85.00Buy → Hold
    Stifel
    5/30/2024$83.00Sell
    Goldman
    More analyst ratings

    $MDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medtronic upgraded by Wolfe Research

    Wolfe Research upgraded Medtronic from Underperform to Peer Perform

    6/30/25 7:56:30 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Leerink Partners initiated coverage on Medtronic with a new price target

    Leerink Partners initiated coverage of Medtronic with a rating of Outperform and set a new price target of $110.00

    6/16/25 7:51:25 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic upgraded by Citigroup with a new price target

    Citigroup upgraded Medtronic from Neutral to Buy and set a new price target of $107.00 from $92.00 previously

    3/4/25 7:37:34 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medtronic announces Board appointments and shareholder value creation initiatives to advance strategic priorities

    Experienced executives John Groetelaars and Bill Jellison appointed to the Board of Directors Board forms new Growth and Operating committees to sharpen focus on the company's ongoing strategic portfolio management, operational execution and capital allocation Plan to host Investor Day in 2026 Initiatives follow constructive engagement with Elliott Management GALWAY, Ireland, Aug. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the Medtronic Board of Directors has appointed John Groetelaars and Bill Jellison as independent directors, effective immediately. Consistent with the company's commitment to shareholder value creation, and

    8/19/25 6:46:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic reports first quarter fiscal 2026 financial results

    11th quarter in a row of mid-single digit organic revenue growth;Poised to accelerate growth GALWAY, Ireland, Aug. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2026 (FY26), which ended July 25, 2025. Key Highlights Revenue of $8.6 billion, adjusted revenue of $8.5 billion, increased 8.4% as reported and 4.8% organicGAAP diluted EPS of $0.81 increased 1%; non-GAAP diluted EPS of $1.26 increased 2%Company raises FY26 EPS guidance; reiterates FY26 organic revenue growth guidanceCardiac Ablation Solutions revenue increased nearly 50%, incl

    8/19/25 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic announces cash dividend for second quarter of fiscal year 2026

    GALWAY, Ireland, Aug. 14, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 14, 2025, approved the company's cash dividend for the second quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on October 17, 2025, to shareholders of record at the close of business on September 26, 2025. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc,

    8/14/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    SEC Filings

    View All

    Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Medtronic plc (0001613103) (Filer)

    8/19/25 6:49:43 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form PRE 14A filed by Medtronic plc.

    PRE 14A - Medtronic plc (0001613103) (Filer)

    8/5/25 5:25:31 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 25-NSE filed by Medtronic plc.

    25-NSE - Medtronic plc (0001613103) (Subject)

    7/2/25 1:17:58 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief HR Officer Walter Matthew R. exercised 3,142 units of Ordinary Shares at a strike of $23.91 and covered exercise/tax liability with 1,910 units of Ordinary Shares, increasing direct ownership by 4% to 31,857 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/4/25 4:21:43 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP & Pres Neuroscience Wall Brett A. covered exercise/tax liability with 11,594 units of Ordinary Shares and converted options into 15,249 units of Ordinary Shares, increasing direct ownership by 7% to 54,937 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/4/25 4:20:26 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP Global Ops & Supply Chain Smith Gregory L converted options into 11,328 units of Ordinary Shares and covered exercise/tax liability with 7,114 units of Ordinary Shares, increasing direct ownership by 6% to 75,957 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/4/25 4:19:29 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Leadership Updates

    Live Leadership Updates

    View All

    Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

    GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

    7/8/25 8:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic Board appoints Dr. Joon Lee as a new director

    GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

    6/23/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

    NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

    3/31/25 4:21:30 PM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    $MDT
    Financials

    Live finance-specific insights

    View All

    Medtronic reports first quarter fiscal 2026 financial results

    11th quarter in a row of mid-single digit organic revenue growth;Poised to accelerate growth GALWAY, Ireland, Aug. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2026 (FY26), which ended July 25, 2025. Key Highlights Revenue of $8.6 billion, adjusted revenue of $8.5 billion, increased 8.4% as reported and 4.8% organicGAAP diluted EPS of $0.81 increased 1%; non-GAAP diluted EPS of $1.26 increased 2%Company raises FY26 EPS guidance; reiterates FY26 organic revenue growth guidanceCardiac Ablation Solutions revenue increased nearly 50%, incl

    8/19/25 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic announces cash dividend for second quarter of fiscal year 2026

    GALWAY, Ireland, Aug. 14, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 14, 2025, approved the company's cash dividend for the second quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on October 17, 2025, to shareholders of record at the close of business on September 26, 2025. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc,

    8/14/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic announces cash dividend for fourth quarter of fiscal year 2025

    GALWAY, Ireland, March 6, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on April 11, 2025, to shareholders of record at the close of business on March 28, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquart

    3/6/25 4:30:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/13/24 5:09:43 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/12/24 1:59:55 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/15/23 3:34:14 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care